"MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome

Inclusion Criteria:

• Age >18 years
• ACS, according to the current definition of the European Society of Cardiology,treated with percutaneous coronary intervention with drug eluting stent implantation
• Occupation and place of residence not causing difficulties in participating in controlvisits
• Uncomplicated course of the disease (ACS) as assessed by the treating physician
• Negative history of diabetes
• Not taking any hypoglycaemic drugs prior to hospitalization immediately or within thelast 6 months
• HbA1c< 6,5% (assessment during hospitalization)
• Written consent to participate in the study

Exclusion Criteria:

• Significant valve disease confirmed by ECHO
• Previous CABG
• NYHA IV during hospitalization
• Chronic kidney disease with GFR <60 ml / min / 1.73 m2 according to MDRD
• ALT three times above normal according to laboratory criteria
• Serious co-morbidities and estimated survival less than 2.5 years, as assessed by thetreating physician
• Known gastrointestinal disease that may potentially be responsible for the intoleranceto metformin (e.g. inflammatory bowel disease, gastro-oesophageal reflux disease)
• Known potential difficulties in cooperation with patients (dementia, mental disorders,distance from the place of residence, if considered potentially problematic,alcoholism)
• Hypersensitivity to metformin
• Pregnancy and breastfeeding
• Patient participation in another clinical trial